Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.

Cell reports. Medicine - 17 Feb 2026

Mikami Takashi, Kato Itaru, Llamas-Covarrubias Mara Anais, Hiramatsu Hidefumi, Uchihara Yoshinori, Mitsuyoshi Takaya, Kitawaki Toshio, Saida Satoshi, Umeda Katsutsugu, Ogawa Seishi, Takaori-Kondo Akifumi, Wing James Badger, Takita Junko

Abstract excerpt

Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy is highly effective for B cell precursor acute lymphoblastic leukemia (BCP-ALL); however, approximately half of the patients relapse. Thus, there is an urgent need to identify factors that improve efficacy. This study enrolls 19 patients with BCP-ALL (16 children and 3 young adults) who receive tisagenlecleucel. Infusion products, peripheral blood, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DR Antigens

Share to Immunotherapy, Adoptive

Share to Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Share to Receptors, Antigen, T-Cell

Share to T-Lymphocytes

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 41579860
DOI: 10.1016/j.xcrm.2025.102576
PMCID: PMC12923955

Genes

CD38
CD19
CXCR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.PMID 41579860Read ↗

Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALLSemantic proximity Read ↗

Single-cell profiling of CAR-T CD19 cell phenotypes and immune system dynamics in pediatric BCP-ALLSemantic proximity Read ↗

Functional diversification and dynamics of CAR-T cells in patients with B-ALLSemantic proximity Read ↗

Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T cell receptor lineagesSemantic proximity Read ↗

Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALLSemantic proximity Read ↗

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphomaSemantic proximity Read ↗

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsSemantic proximity Read ↗

CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignanciesSemantic proximity Read ↗

Tandem CD19/CD22 CAR-T cells conquer high-risk cytogenetics and acquire complete remission in r/r B-ALL patientsSemantic proximity Read ↗

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.Semantic proximity Read ↗

CAR<sup>+</sup> and CAR<sup>-</sup> T cells differentiate into an NK-like subset that is associated with increased inflammatory cytokines following infusionSemantic proximity Read ↗

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasiasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.